Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS) has announced upcoming scientific presentations at two major conferences: the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) in Vienna from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting in San Diego from April 5-9, 2025.

The presentations will highlight the implementation of a validated research-use plasma pTau217 assay in screening participants for the Phase 2 ALTITUDE-AD study of sabirnetug, their novel therapeutic targeting soluble amyloid beta oligomers (AβOs) for early symptomatic Alzheimer's disease treatment.

Key presentations include:

• Oral presentation on ALTITUDE-AD study at AD/PD on April 1
• Two poster presentations at AD/PD focusing on amyloid beta preparation and neuronal binding studies
• Oral presentation on plasma pTau217 screening at AAN on April 7
• Poster presentation on INTERCEPT-AD biomarker results at AAN on April 9

Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug

NEWTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced upcoming scientific presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting in San Diego, Calif., from April 5-9, 2025.

Oral presentations will focus on implementation of a validated research-use plasma pTau217 assay in the clinical trial participant screening process. Poster presentations will focus on methods of interrogating the binding of AβOs to a model of human neurons; methods to more accurately assess the AβO selectivity of nonclinical assays and sabirnetug; and early effects of sabirnetug on synaptic biomarkers in AD. Together, these presentations support the comprehensive development program for sabirnetug, which Acumen is advancing as a potential next-generation antibody treatment for early symptomatic AD.

AD/PD presentation details are as follows:

Oral Presentation

ALTITUDE-AD: Use of Plasma pTau217 Screening in An Ongoing Phase 2 Study of Sabirnetug for Early Symptomatic Alzheimer's Disease (2813)

• Date/Time: April 1, 2025, 2:30-2:45 p.m. CEST
• Location: Austria Center Vienna, Hall A
• Presenting Author: Eric Siemers
  

Poster Presentations

Protocol for the Preparation of Stable Monomeric Amyloid Beta (1522)

• Dates: April 2-3, 2025
• Location: Austria Center Vienna, Exhibition Hall
• Presenting Author: Erika Cline
  

Utility of Human iPSC-Derived Neuronal Model for Evaluating Synaptic Binding of Amyloid Βeta Oligomers (1393)

• Dates: April 2-3, 2025
• Location: Austria Center Vienna, Exhibition Hall
• Presenting Author: Elizabeth Johnson
  

AAN presentation details are as follows:

Oral Presentation 

ALTITUDE-AD: Use of Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Alzheimer's Disease (3870)

• Date/Time: April 7, 2025, 2:24 p.m. PT
• Location:  San Diego Convention Center, 25C
• Presenting Author: Todd Feaster
  

Poster Presentation 

INTERCEPT-AD Biomarker Results: Early effect of sabirnetug treatment on synaptic biomarkers in Alzheimer's disease (3984)

• Date/Time: April 9, 2025, 11:45 a.m. – 12:45 p.m. PT
• Location: San Diego Convention Center, Poster Hall
• Presenting Author: Elizabeth Johnson
  

About Sabirnetug (ACU193)

Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.

About ALTITUDE-AD (Phase 2)

Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study will enroll approximately 540 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD). The global study is currently ongoing at multiple investigative sites located in the United States, Canada, UK, and the European Union. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “potential,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning the therapeutic potential and potential clinical efficacy of Acumen’s product candidate, sabirnetug (ACU193). These statements are based upon the current beliefs and expectations of Acumen’s management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.

Investors:
Alex Braun
abraun@acumenpharm.com

Media:
Jon Yu
ICR Healthcare
AcumenPR@icrhealthcare.com

FAQ

What are the key findings Acumen Pharmaceuticals (ABOS) will present at AD/PD 2025?

Acumen will present findings on plasma pTau217 assay implementation in ALTITUDE-AD study screening, methods for AβO binding to neurons, and sabirnetug's effects on synaptic biomarkers in Alzheimer's disease.

When and where will ABOS present their ALTITUDE-AD study results in 2025?

The ALTITUDE-AD study results will be presented at two conferences: AD/PD in Vienna on April 1, 2025, and AAN in San Diego on April 7, 2025.

What is the focus of Acumen's (ABOS) Phase 2 ALTITUDE-AD clinical trial?

The ALTITUDE-AD trial studies sabirnetug, a novel therapeutic targeting soluble amyloid beta oligomers (AβOs) for early symptomatic Alzheimer's disease treatment.

How many presentations will ABOS deliver at the 2025 AD/PD conference?

ABOS will deliver three presentations at AD/PD 2025: one oral presentation on ALTITUDE-AD and two poster presentations on amyloid beta preparation and neuronal binding studies.

What biomarker data will ABOS present at the 2025 AAN meeting?

ABOS will present INTERCEPT-AD biomarker results showing early effects of sabirnetug treatment on synaptic biomarkers in Alzheimer's disease on April 9, 2025.